The antibodies used for this study were AMYLASE (A8273; Sigma-Aldrich), Atg5 (PM050, MBL, Woburn, MA), phos-TFEB (ABE1971; Millipore, Burlington, MA), TFEB (A303-673A; Bethyl Laboratories, Montgomery, TX), CK19 (TROMA-III, Developmental Studies Hybridoma Bank, Iowa City, IA), GAPDH (2118; Cell Signaling Technology, Danvers, MA), p62 (H00008878-M01; Abnova, Taipei, Taiwan), phos-4EBP1 (9451; Cell Signaling Technology), 4EBP1 (9452; Cell Signaling Technology), phos-MAPK (9101; Cell Signaling Technology), MAPK (9102; Cell Signaling Technology), phos-S6-ribosomal protein (4858; Cell Signaling Technology), S6-ribosomal protein (2217; Cell Signaling Technology), GFP (sc-9996; Santa Cruz Biotechnology, Dallas, TX), LAMIN A/C (2032; Cell Signaling Technology), LAMP1 (1D4B and H4A3; Developmental Studies Hybridoma Bank, Iowa City, IA), LAMP2 (ABL-93 and H4A4; Developmental Studies Hybridoma Bank), and PGC1α (PAB12061; Abnova). The TAP antibody was generated by Thomas Kolodecik from Yale University.45 (link) Antibodies for VATP6V1a and VATP6V1b2 are gifts from Dr. Dennis Brown from Harvard Medical School. The Anti-LC3 antibody was generated as previously described.43 (link) HRP-conjugated, FITC-conjugated and Rhodamine-conjugated secondary antibodies were from Jackson ImmunoResearch (West Grove, PA).
Free full text: Click here